# Neo-Adjuvant FOLFOX for Rectal Carcinoma

> **NCT00832299** · PHASE2 · TERMINATED · sponsor: **Beth Israel Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **DRUG:** FOLFOX
- **PROCEDURE:** total mesorectal excision (TME)

## Key facts

- **NCT ID:** NCT00832299
- **Lead sponsor:** Beth Israel Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** terminated for lack of enrollment
- **Last updated:** 2018-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832299, "Neo-Adjuvant FOLFOX for Rectal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00832299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*